Tactile Medical/$TCMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tactile Medical
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Ticker
$TCMD
Sector
Primary listing
Employees
1,037
Headquarters
Website
Tactile Medical Metrics
BasicAdvanced
$342M
24.55
$0.63
0.96
-
Price and volume
Market cap
$342M
Beta
0.96
52-week high
$18.92
52-week low
$8.61
Average daily volume
167K
Financial strength
Current ratio
3.787
Quick ratio
3.206
Long term debt to equity
18.532
Total debt to equity
21.636
Interest coverage (TTM)
10.33%
Profitability
EBITDA (TTM)
25.669
Gross margin (TTM)
74.72%
Net profit margin (TTM)
5.06%
Operating margin (TTM)
6.30%
Effective tax rate (TTM)
26.90%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
4.27%
Return on equity (TTM)
7.64%
Valuation
Price to earnings (TTM)
24.554
Price to revenue (TTM)
1.217
Price to book
1.76
Price to tangible book (TTM)
2.78
Price to free cash flow (TTM)
9.212
Free cash flow yield (TTM)
10.86%
Free cash flow per share (TTM)
1.666
Growth
Revenue change (TTM)
6.15%
Earnings per share change (TTM)
-53.99%
3-year revenue growth (CAGR)
10.44%
10-year revenue growth (CAGR)
18.46%
3-year earnings per share growth (CAGR)
-26.30%
10-year earnings per share growth (CAGR)
47.09%
What the Analysts think about Tactile Medical
Analyst ratings (Buy, Hold, Sell) for Tactile Medical stock.
Bulls say / Bears say
Tactile Systems delivered 7.8% year-over-year revenue growth in Q2 2025 to $78.9 million, driven by a 52% increase in airway clearance (AffloVest) sales and a 2% rise in lymphedema product revenue (GlobeNewswire)
The company completed its $30 million share repurchase program in Q2, buying back $16.5 million of common stock and signaling strong capital allocation discipline (GlobeNewswire)
Tactile Systems expanded its commercial organization to 293 sales representatives in Q2 and targets over 300 reps by year-end, supporting broader market penetration (Investing.com)
Net income dropped 25% to $3.2 million and adjusted EBITDA declined 15% to $7.7 million in Q2 2025 as operating expenses rose 13% to $54.7 million, indicating profit pressure from ongoing strategic investments (GlobeNewswire)
In Q1 2025, Tactile Systems reported a $0.13 EPS loss versus an expected $0.08 loss and revenues of $61.3 million versus $64.5 million anticipated, triggering a 25% pre-market share plunge and highlighting execution risks (Investing.com)
Management lowered full-year 2025 revenue guidance to $309–315 million from $316–322 million and saw shares fall 23.5% in pre-market trading, underscoring investor concerns about growth visibility (Ainvest.com)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2025.
Tactile Medical Financial Performance
Revenues and expenses
Tactile Medical Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tactile Medical stock?
Tactile Medical (TCMD) has a market cap of $342M as of October 30, 2025.
What is the P/E ratio for Tactile Medical stock?
The price to earnings (P/E) ratio for Tactile Medical (TCMD) stock is 24.55 as of October 30, 2025.
Does Tactile Medical stock pay dividends?
No, Tactile Medical (TCMD) stock does not pay dividends to its shareholders as of October 30, 2025.
When is the next Tactile Medical dividend payment date?
Tactile Medical (TCMD) stock does not pay dividends to its shareholders.
What is the beta indicator for Tactile Medical?
Tactile Medical (TCMD) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.